

INVEST IN KOIOS MEDICAL, INC

AI-powered software diagnosing cancer. Super-human accuracy. Proven. Billable. Lifesaving.

koiosmedical.com New York, NY



Highlights

- 1 Massive, rapidly growing emerging market for AI, medical imaging and ultrasound in particular.
- 2 AI disrupting radiology. Growing network of clinical champions worldwide. 500+ sites use daily.

- 3 Reimbursement eligible. Applicable CPT Codes (0689T, 0690T) issued. FDA, CE mark hurdles cleared.
- 4 Investment terms same as lead strategic institutional investor, Mitsui & Co (Japan). >60% funded.
- 5 \$1.6B annual market opportunity. Growth via new product opportunities. Limited to no competition.
- 6 Stellar management team. Proven track record. Growing network of world class clinical advisors.
- 7 12 Patents, 2M+ images; 11 peer reviewed, published studies. Growing body of clinical evidence.
- 8 Distribution partnerships with GE Healthcare, Philips, Sirona Medical and more in the works.

Featured Investors



Peter Billmeyer 

Invested \$350,000 

Follow

Syndicate Lead

Founder, CEO Bespoke Limited Ventures

"I first learned about Koios Medical and AI powered ultrasound back in 2017. I was initially intrigued but cautious, knowing how few great ideas become breakthrough successes both clinically and commercially. Physician family and friends expressed caution, cognizant of the challenges ahead. Regulatory approvals, validation studies, physician adoption overcoming entrenched methods in addition to the potential for competition facing any new product innovation in medicine. Aware of the risks but knowing the track record of management, preliminary clinical results and the unique opportunity and company position I proceeded with cautious optimism.

Fast forward to today. What an amazing story Koios Medical has become. Approved

around the world, funded in part by Mitsui & Co and other experienced healthcare investors. Adopted by hundreds, soon to be thousands of physicians. Making an impact in ways I find personally rewarding, impacting the lives of people with disease, their families and communities.

Koios is the category leader with arguably little to no competitors. Fundamentals, given the industry and stage continue to improve while significant risks effectively managed down or out. A company that endured Covid emerging with a strong value proposition for hospitals, clinics, governments, payers and certainly patients.

As an active investor, I see a large volume of deals. Very few possess the track record, moat and potential of Koios. The expansion opportunities within a rapidly growing market for a patented product already in market with strong distribution and a first mover advantage. Combined all that with a crowdfunding community poised to drive awareness that includes physicians, customers, partners, even patients, families and advocates for cancer diagnosis and technology innovation now involved in the growth makes the future for Koios even more compelling.

The healthcare workforce shortage is real. Many things must be done and Koios Medical is uniquely positioned to be part of a larger transformation of healthcare already underway with artificial intelligence at the core.""

Other investors include [Mitsui & Co.](#), [Bold Brain Ventures](#)

Our Team



Chad McClennan President & CEO

Leader of the company, inspired to make an impact in the lives of physicians, patients, families and society. Previous co-founder of medical software company sold to Stryker. Advised healthcare, technology companies Humana, Chapters Health System, others.



Graham Anderson Chief Financial & Administrative Officer



Stanislav Anderson Chief Financial & Administrative Officer

Experienced in finance across verticals including healthcare, IT services and consumer products. Former VC turned operator helping guide our company and serve our shareholders.



Ajit Jairaj Vice President - R&D

Initially designed face recognition for the US DoD and pivoted into analyzing suspicious ultrasound exams and now oversees the brilliant Koios Medical research and development engineers.



Jon Robinson Vice President - Software Product

Two decades of experience designing, delivering, and supporting radiology software products to the largest radiology providers globally.



Omar Partida Chief Development Officer

Established national breast cancer screening programs across the Gulf region, introducing and implementing innovative radiology technologies. Coordinates Koios' efforts across our growing network of channel partners.



Bill Hulbert VP Software Development

Building great software! Overseas and manages all layers of Koios application development to ensure quality, secure and reliable solutions for Koios customers.

Invest in software with vision.

We put the AI in ultrasound.

WeFunder Community Campaign

CONFIDENTIAL

We are excited to introduce you to our exciting story, the future of SmartUltrasound and offer an investment opportunity normally reserved for, exclusive to professional, institutional investors and VC firms.

Koios Medical, Inc

The global leader in AI software as a medical device (SaMD) for the accurate diagnosis of breast and thyroid cancers improving clinical outcomes and workflows applying deep learning to the lowest cost, safest and most widely available imaging modality in the world, ultrasound.
SmartUltrasound™

The first breast ultrasound exam interpretation supported by Koios SmartUltrasound was read by Dr. Lai Ming Yu in New York City on March 9, 2018. Since then, we have grown steadily, expanded our offering and now support physicians across the US and in 20+ countries around the world.

Harvard Public Health

*The patient wants
a second opinion
from an AI*

February 15, 2024



By Natasha Loder

Recent surveys found patients prefer receiving care from physicians supported by AI more than two (67%) to one (29%) versus physicians acting alone.

Value Proposition

Reimbursement: Promise to Reality

As of January, 2022 use of Koios DS became a billable procedure (USA).

"We found that the overall utilization of medical AI products is still limited and focused on a few leading procedures.

However, utilization has generally increased exponentially for each medical AI procedure."

James Zou, PhD et al

The NEW ENGLAND JOURNAL of MEDICINE

November 9, 2023

ORIGINAL ARTICLE

Characterizing the Clinical Adoption of Medical AI Devices through U.S. Insurance Claims

Kevin Wu¹, M.S.,¹ Eric Wu², M.S.,² Brandon Theodorou³,⁴ Weixin Liang⁵, M.S.,² Christina Mack⁶, Ph.D.,² Lucas Glens⁷, Ph.D.,² Jimeng Sun⁸, Ph.D.,^{2,9} and James Zou^{1,2}, Ph.D.^{1,2,10}

Received: July 9, 2023; Revised: September 15, 2023; Accepted: September 28, 2023; Published: November 9, 2023

Abstract
There are now over 500 medical artificial intelligence (AI) devices that are approved by the U.S. Food and Drug Administration. However, little is known about when and how often they are used.

Table 1. Summary of AI CPT Codes.*

Total Claims	Condition or Medical AI Procedure	CPT Code(s)	Example Product Name	Effective Date
47,306	Coronary artery disease	95017-95047	HeartFlow Analysis ¹¹	June 1, 2018
15,887	Diabetic retinopathy	92229	LumineticsCare ¹²	January 1, 2021
5,458	Coronary atherosclerosis	92327-92427	Clarity ¹³	January 1, 2021
2,478	Liver MR	94487-94497	Perspectum LiverMultiScan ¹⁴	January 1, 2021
199	Multislice MRI	96977-96987	Perspectum CoverScan ¹⁵	January 1, 2022
152	Breast ultrasound	94897-94907	Koios DS ¹⁶	January 1, 2022
419	TKA cartilage thickness	91044-91051	Acumina ¹⁷	January 1, 2022
331	Cardiac acoustic waveform recording	92787	CADSO ¹⁸	July 1, 2022
227	Quantitative MR cholangiopancreatography	92237-92247	Perspectum MRCP ¹⁹	July 1, 2022
67	Epidural infusion	87277	CompuFlow ²⁰	January 1, 2023
4	Quantitative CT fibrotic characterization	92117-92127	Opstrone Virtual Nodule Clinic ²¹	July 1, 2022
1	Autonomous insulin dosing	92407-92417	diRx ²²	January 1, 2023
1	CT vertebral fracture assessment	00817	HealthVista ²³	January 1, 2022
1	Noninvasive arterial plaque analysis	07107-07117	EluoVivo ²⁴	January 1, 2022
0	Facial phenotypic analysis	67911	FaceGen ²⁵	July 1, 2022
0	Key bone density	82697	Genologix ²⁶	January 1, 2013

* A total of 16 medical AI procedures are presented alongside their corresponding CPT codes. Each procedure is associated with an example commercial product that may be reimbursed through the codes. The effective date is the date on which the code was officially recognized by the American Medical Association and can be used for billing and reimbursement purposes. The total claims listed are recent as of June 1, 2023. AI devices artificial intelligence; CPT, Current Procedural Terminology; CT, computed tomography; ECG, electrocardiogram; MR, magnetic resonance imaging; MRCP, magnetic resonance cholangiopancreatography; and MRI, magnetic resonance imaging.

recently, with 15 of 16 medical AI procedures created since 2021 (Fig. 1). We found that only 4 of 16 have more than 1000 total claims. This is partially because the median age of a medical AI procedure is only about a year (374 days).

GROWTH PATTERNS OF MEDICAL AI DEVICES
We found that the overall utilization of medical AI products is still limited and focused on a few leading procedures.

Diabetic retinopathy medical AI has also grown exponentially in usage (n=15,097, effective January 1, 2021). The first FDA approval in this category was given on January 12, 2018, to LumineticsCare¹², an AI diagnostic system that autonomously diagnoses patients for diabetic retinopathy (including macular edema).²² It is indicated for use by health care providers to automatically detect more than mild diabetic retinopathy in adults diagnosed with diabetes who have not been previously diagnosed with diabetic

Ranked #6 of most frequently billed AI solutions of the more than 700 AI solutions cleared by the FDA; all in less than 18 months since codes for the use of Koios DS were made available. Research indicates the availability of billing codes can lead to utilization that grows "exponentially".

Situation

Situation

AI-powered software for ultrasound imaging and workflow optimization is poised to super-charge an already booming market.

Projected market value of ultrasound, by 2028.

\$13B


The global medical imaging AI market is expected to exceed \$14B over the next decade.

\$14B

Source: [managedhealthcareexecutive.com](https://www.managedhealthcareexecutive.com) (Dec 2023)

CONFIDENTIAL

Koios Medical operates at the intersection of two of the highest growth segments in healthcare and business overall: Ultrasound is the highest growth imaging modality, AND medical AI is forecasted for double digit growth over the next five years. Pending breast density notification going into effect in September is expected to spark a resurgence in ultrasound (demand) as a supplemental to mammograms for women with dense tissue.



“

Having evaluated the majority of radiology AI solutions on the market, I can confidently say Koios SmartUltrasound has emerged as a leader and role model for others. Excellent use cases combined with a compelling value proposition and an outstanding team.

Dr. Shah Islam

University College London Hospital NHS (England)


CONFIDENTIAL

Problems we must solve



A critical **shortage of radiologists** around the world.

Breast and thyroid **cancer incidence is on the rise.**




Found in younger patients more than ever before.

Ultrasound image interpretation can be challenging. Accuracy and variability in diagnosing cancers is **fraught with errors** and low clinical confidence.

New legislation is poised to **drive up ultrasound** use.

Economic and ethnic **disparities abound**.

Koios Medical's software was designed at the outset to pinpoint multiple pain points plaguing healthcare systems worldwide; specifically radiology, the mega service line that spans across all medical specialties. A "one to many" relationship exists whereby a single software solution can elevate quality, control costs, save time and help close the health equity gap simultaneously.



Problems we MUST solve




80% of breast biopsies performed **are negative**. Benign.

95% of thyroid biopsies performed **are negative** or inconclusive.

Yet **doctors miss 100K+ breast cancers** every year in the US alone.

A cancer **found early has 99% 5 year survival** vs. 50% when cancers are found later as treatment costs increase 10x.

Lives are at stake. Although many solutions offer a promising range of benefits, few can match the life-saving impact of early cancer detection and accurate diagnosis. \$1.6B is spent annually in the US on breast biopsies of which \$1.3B are benign, negative; YET tens of thousands of breast and thyroid exam still miss, or deem as "interval cancers" to be found later, often after the possibility of effective treatment. Koios SmartUltrasound is already saving lives along with ultimately millions of dollars and hours of time wasted on avoidable procedures and too late-stage treatments.




A Multi-Society Statement from the ACR, CAR, ESR, RANZCR and RSNA.

“

Artificial Intelligence (AI) is likely to be the **single most-disruptive influence** on radiology in many decades, and potentially since the very beginnings of our specialty...

Artificial intelligence offers the possibility of change that **goes far beyond previous disruptions.**

(Jan 2024)




SmartUltrasound was created from amassing a dataset comprised of what has grown to over 2M images along with pathology data that distills images down to the pixel level for patterns that are invisible to the human eye, building models that predict cancer and distinguish normal tissue with startling and ever increasing accuracy. Trillions of pixels tell a story that saves lives and reduces the need for the cost and stress of more crude methods of today.

SmartUltrasound


Scalable, accurate,
simple, fast.

On scanner, at your
workstation, in your
reports.




Our software is designed and built to meet the needs of clinicians from on-scanner in the ultrasound exam room to the reading workstation and into reports. Vendor agnostic built upon image data from all major ultrasound scanners across all major ethnicities. Built for a global community of users and patients to improve accuracy, consistency and optimize cumbersome workflows.

Product

Available on GE LOGIQ scanners 

We're with you from imaging to reporting.

- AI integrated, on scanner
- Seamless usability
- One-click analysis
- POCUS Compatible
- Works in your workflow



The screenshot shows the GE LOGIQ ultrasound software interface. At the top, it displays patient information: "GE Healthcare 03/27/23 01:08:49PM ADM Thyroid Koios Demo 23". The main display area shows two ultrasound images of a thyroid gland with yellow circles highlighting specific nodules. A central pop-up window displays a "1" and the text "No PNA" and "Mixed cystic and solid". Below this, there are buttons for "Accept", "Review", and "Dismiss". On the left side of the interface, there is a list of measurements: "1 Rt. Nodule H 1.11 cm", "Rt. Nodule L 1.60 cm", "Rt. Nodule AC Area 1.33 cm²", "2 Rt. Nodule H 1.18 cm", "Rt. Nodule W 1.50 cm", "Rt. Nodule AC Area 1.33 cm²". At the bottom of the interface, there is a navigation bar with a "Koios" button highlighted in blue. The "Koios" button has a white owl icon on it. The bottom right corner of the interface has the word "CONFIDENTIAL" and a "Cursor Select" label.

Simply select the Koios Owl button directly on the touch panel of any GE LOGIQ scanner and instantly obtain a cancer risk assessment aligned to BI-RADS or TI-

RADS that can be edited, saved or disregarded, improving timeliness of interpretation with fewer reporting errors. Coming soon to the touch panel of other major manufacturers.

Product PACS Viewer

Thyroid AI Analysis

Diagnose nodules more quickly and accurately.

- Aligns to TI-RADS or ATA
- Auto-populates descriptors
- Fine-tune risk level with AI adapter
- Export directly to reporting software

MRN: P-0169-DD36-DB04
DOB: INVALID DATE

Copy All Save

N1 N2 N3 N4 N5

5 Highly Suspicious
FNA
8 pts = 6 pts + 2 3.34 cm > 1 cm

ACR TI-RADS® DESCRIPTORS

Solid Or Almost Completely Solid	2 ▶
Hyperechoic Or Isoechoic	1 ▶
Wider-Than-Tall	0 ▶
Lobulated Or Irregular	2 ▶
Macrocalcifications	1 ▶

Koios AI Adapter +2

Left Mid position
Anterior
3.27 x 3.34 x 2.56 cm

TRV
Image 14 of 61

LONG
Image 14 of 61

Multiple suspicious nodules captured in a thyroid ultrasound exam receive a full and thorough assessment, classified and a draft report prepared aligned to TI-RADS and ready for review. Modify or export directly into patients' reports.

Product PACS Viewer

Breast AI Analysis

Quick, intuitive and easy to use.

- AI independent classification
- Aligns to BI-RADS
- Analyzes in seconds
- Export directly to reporting software

MRN: P-E80A-8340-047B
DOB: INVALID DATE

Copy All Save

F1 F2 F3 F4

M Probably Malignant
Risk Alignment:
BI-RADS 4C+

ACR BI-RADS® DESCRIPTORS

shape	Irregular
orientation	Parallel


Left breast
9:00 position
1 cm/in
1.378 x 1.566 x 1.332

Image 11 of 12

Image 12 of 12

Ultrasound breast exams, particularly valuable to women with dense breast

Ultrasound breast exams, particularly valuable to women with dense breast tissue, benefit from a thorough cancer risk assessment aligned to BI-RADS to be saved, edited and exported directly into patients' reports.


Product 

Auto-generate reports


Save time with automated reporting.

- Export results with one click*
- Copy/paste findings into any document
- Auto-fills into mapped fields

*When integrated with reporting software



Full reports can be populated at the lesion or nodule level with each appropriate descriptor category populated, TI-RADS scores calculated and exported into a consistent, customized report template complete with CPT Codes and language to facilitate accurate billing.

Problem 

“
Uncontrolled variation is the enemy of quality.”

W. Edwards Deming
1980

Radiologists with comparable training and experience disagreed with each other's diagnosis **36%** of the time

Physicians changed their own initial diagnosis when presented with the same case a month later. **20%** of the time


American Journal of Roentgenology April 2020
Victoria L. Mango, Mary Sun, Ralph T. Wynn, and Richard Ha

Why is Koios DS SmartUltrasound software SO important? Nobody is correct 100% of the time. In fact, Koios' and other studies have found physicians can disagree with one another on examination interpretation more than 1/3 of the time AND will change their minds on the same exam one of every five times. Variability in interpretation leads to errors. Medical mistakes are the 3rd leading cause of death in the US. Use of Koios software dramatically reduces variability by >40%.

Evidence

Our AI makes everyone better.

Sensitivity (avg.)	97-99%	More cancers found	6%
Specificity (avg.)	61%	Biopsies avoided	31%




Koios' landmark study was comprised of 15 physicians across all experience levels and found significant improvements to both sensitivity (cancer detection) and specificity (benign determination) leading to significant improvements to the overall quality of care and patient outcomes (at lower costs).

Evidence

Our AI makes everyone faster.

Sensitivity (avg.)	+14%	Variability	-41%
Specificity (avg.)	+37%	Interpretation time	-24%





Not only was quality improved, but significantly LESS time was required when studying physician interpretation times.

Evidence

11

Peer-reviewed retrospective studies


20


Posters and abstracts

50*


Validation studies

*And counting






“
The AI DS accurately characterized 100% of detected ILC lesions as suspicious or probably malignant.
[Clinical Imaging May/Sept 2023](#)
Tali Amir, Kristen Coffey, Varadan Sevilimedu, Reza Fardanesh, Victoria L. Mango



“
Artificial intelligence decision support aid may help improve sonographic diagnostic accuracy, ... decreasing false-positives.
[Ultrasound Quarterly March 2021](#)
Samantha L. Heller, PhD, MD; Melanie Wegener, MD; James S. Babb, PhD; Yiming Gao, MD




“
Our results suggest that software like this could potentially reduce the number of unnecessary breast biopsies.
[2020 SBI ACR Breast Imaging Symposium](#)
Joseph Cavallo, MD 2020 Wendell Scott Research Award Recipient
Fellow, Emergency Radiology & Healthcare Leadership
Yale Department of Radiology

All studies performed to date all indicate the same, powerful and exciting conclusion: Koios SmartUltrasound software when used properly and in accordance with its indications can lead to significant improvements in cancer detection while simultaneously eliminating avoidable benign biopsy procedures and unnecessary follow-up appointments for patients.

Evidence

It's happening, AI outperforms.

A Comparison of AI Vendor Algorithms for Stand-Alone Lung Nodule Detection on Chest X-Rays




→ Multiple AI solutions have begun to consistently outperform physicians.

→ Several companies, clinical use cases.

→ **Koios SmartUltrasound + physicians consistently outperforms physicians**






Source: Lesauwen KG, Schalekamp S, Ruiten MJC, et al. Comparison of commercial AI software performance for radiograph lung nodule detection and bone age prediction. *Radiology*. 2023;210(1):e23091. Doi: 10.1148/radiol.2023091. On line ahead of print. (Editor's note: Sensitivity and specificity percentages for the Annalise.ai and Oxipit algorithms were not available in the study.)


alone.

CONFIDENTIAL

AI is outperforming physicians alone in other clinical applications as well. A recent study demonstrated how several solutions performed relative to physicians interpreting the same exams. NOTE: Koios is indicated for use as a second opinion, to complement and augment clinical decision-making.



Key metrics: User and adoption growth has experienced double and triple digit gains since emerging from the Covid challenged period that began March, 2020. Adoption growth is the precursor to revenue we anticipate in the future as trials and pilots convert to commercial terms.



New Jersey	Lithuania	Argentina
New York	Moldova	Chile
North Carolina	Morocco	Peru
Ohio	Netherlands	Guyana
Pennsylvania	Romania	Ecuador
Rhode Island	Saudi	Uruguay
Texas	Spain	Brazil
Vermont	Turkey	
Virginia	UAE	
Washington	United Kingdom	
Canada	Qatar	

30+
research sites

*as of Nov 2023

CONFIDENTIAL

Traction



Adoption

Forward-thinking organizations around the world are discovering the value of SmartUltrasound™

and many more...

CONFIDENTIAL

A sampling of customer institutions and organizations (willing to allow us to display their names). Many of the leading cancer centers in the US are customers and/or research partners among a rapidly growing installed base.

Competition & IP



Competitive Landscape

	Ultrasound	X-ray/Mammo	CT-scan	MRI
Breast	Koios Samsung Qview SeeMode	Kheiron CureMetrix iCAD, Screenpoint Deep Health Therapixel, Lunit		Clarity Formerly QuantX
Thyroid	Koios AmCad MEDO			
Lung/Chest		(several)	Riverrain AI doc	
Brain			Viz.AI AI doc Others	(Several)
Abdomen	Butterfly		GE	Resonance
Heart	Caption Health Heart Flow		Siemens TomTec	Arterys (several)

Ultrasound + AI Market

No other known vendor agnostic players with full FDA clearance and CE Marked decision support commercially available.

- Samsung S-Detect (on-scanner): *x not FDA cleared*
- AmCad (Thyroid): *x not FDA cleared*
- MEDO (Thyroid): Medo acquired by Exo
- Qview (ABUS (automated breast)): *x detection only*
- See-Mode: *x not FDA cleared*


Koios is differentiated and uniquely well positioned against any competition based on the large, growing curated image dataset, IP, regulatory status, product performance, distribution, installed base and "first in market" on physician screens and on hardware position; presenting numerous formidable barriers to entry.

> 2M image dataset linked to pathology and ground truth sources from a diverse international population of patients

Koios enjoys a first mover advantage and a unique position with limited to no known viable competition worldwide. Other ultrasound AI players either lack similar capabilities or are yet to receive regulatory approvals and clearances.



A "go to market" strategy and plan in full execution mode. Targeted customers being reached through a coordinated effort of campaigns, conferences and distribution partners with flexible, value-based pricing. Our global distribution network included GE Healthcare, Philips, Sirona Medical and many other leading regional and local entities.



\$12K/year/scanner

Reimbursement Support

\$10K - \$25K/year

Reimbursement Support

\$25K - \$75K/year

Reimbursement Support

> \$100K/year

Reimbursement Support

CONFIDENTIAL


Annual subscription pricing tailored to the size of any customer. Investments in Koios software typically costs far less than the gains, efficiencies seen and amounts eligible for reimbursement, typically delivering a payback measured in months. Arguably the strongest value proposition available of any radiology AI solution.

TAM



Total Market Opportunity: >\$1.6B worldwide⁽²⁾. Limited competition.

8+ million SmartUltrasound™ Breast & Thyroid eligible exams per year (US only)
@\$50/exam⁽¹⁾ = \$300M annually



(1) Conservative reimbursement estimate
(2) \$1.6B TAM includes thyroid ultrasound volumes only

CONFIDENTIAL

Millions of traditional diagnostic exams per year are now eligible, candidates for the use of Koios SmartUltrasound, creating a substantial market opportunity for Koios and our distribution partners.



Leadership Team & Advisors



Chad McClennan
President & CEO



Graham Anderson
Chief Financial Officer



Jonathan Robinson
VP Product Management



Omar Partida
Chief Development Officer





Lev Barinov, MD PhD
VP Clinical Excellence



Ajit Jairaj
VP Research & Development

Board of Directors

Dr. Mark Glasgold *Chairman*
Chad McClennan
Gregory Moran
Christine Li



Prior Relevant Experience:

Hologic
Stryker
RadNet
Intelerad
Kheiron
Salesforce.com

Bill Hulbert
VP Software Development

Jo Barnes
Enablement & Engagement

Robin Allman
E & E, Koios Academy

Ethan Green
Technical Product Manager

Michael Bocchinfuso
Director Regulatory & Quality

Dr. Luis Lehmann
Clinical Advisor LATAM

US Defense contractor
INVIA
Urolift
UPenn Medicine

Strategic, Scientific Advisors, Research Partners & Community of Koios KOLs

Dr. Wendie Berg
Dr. Bill Middleton
Dr. Ari Jonisch

Dr. Jack Crowe
Dr. Vladimir Necklesa
Phillip Lynch, PhD

Dr. Ed Grant
Dr. Bruce McClellan
Dr. Hugh Harvey

Dr. Shah Islam
Dr. Richard Ha
Dr. Amy Patel

Prof. Winston MA
Dr. Laurie Margolies
Dr. Flavia Sarquis


Dr. Erkin Aribal
Dr. Gerald Lip
Dr. Timothy Dyer

Dr. Ross Filice
Dr. Nisha Sharma
Dr. Kardinah

Dr. Vikki Mango
Dr. Daniel Mysler
Dr. Kristen Coffey


CONFIDENTIAL

A seasoned team with a common purpose and mission. All with a vested interest in the future success of the company.



Growth projected for 4-5 years in the future may offer an opportunity for investors to exit through either acquisition or future financing rounds used for additional product and market development, expansion. Future projections not guaranteed.





- OEM licensing, development fees & royalties
- Grants
- Additional products

CONFIDENTIAL

Current forecasts indicate the potential for achieving cashflow neutral to positive by the end of 2025. This current raise could be sufficient to achieve that important milestone. Note that future projections are not guaranteed.

Investment Opportunity



Series B Equity: Mitsui & Co + Koios Community

- Valuation:** \$60M (pre-money)
- Amount Available:** \$5M of \$13M total
- B Round Lead:** Mitsui & Co(Japan)/MBK Healthcare (Singapore): largest shareholder IHH Health. \$8M committed, funded.
- Market Opportunity:** > \$1.6B (no known viable competitors)
- Prior (Series A) Round:** \$10M raised at \$25M (pre-money)

Koios Medical has efficiently utilized \$34 million in seed and venture capital since its inception in 2012. Currently, the company is in the process of raising an additional \$5 million through WeFunder, in conjunction with a Series B round led by Mitsui & Co, of which \$8 million has already been committed and funded.

Our objective is to source incremental funds from a diverse network of passionate individuals dedicated to innovation and enhancing healthcare. WeFunder provides an avenue for Koios to extend this investment opportunity to physician customers, patients, partners, and other healthcare investors that might otherwise be restricted to institutional investors.

With Mitsui as the largest shareholder in IHH Healthcare and our global community of physician customers, partners, and individual investors, we are confident that Koios will be well-positioned to execute its aggressive growth strategy. Our ultimate aim is to establish Koios as the global standard for diagnostic ultrasound, reducing missed cancer diagnoses, facilitating early cancer detection, optimizing workflows, expediting reimbursement processes, and fostering rapid global commercial expansion.

Koios Medical has already demonstrated promising results in the US market, with multiple private payers reimbursing our SaMD technology under recently approved CPT codes (0689T, 0690T) applicable to both Koios DS Breast and Thyroid SmartUltrasound AI software. Additionally, the newly created Medicare Transitional Coverage for Emerging Technologies (TCET) presents another favorable payment framework opportunity through CMS.

Furthermore, the growing shortage of clinical resources worldwide, coupled with the escalating imaging workload, underscores the urgent need for an innovative imaging solution to enhance productivity and prevent lapses in care, excessive treatment costs, and loss of life.

The allocated funds will primarily be deployed as working capital to support commercial expansion, ongoing market and product development, enhancing efficiency for physicians and technicians, reimbursement efforts, and continued support for our expanding customer base transitioning to commercial customers and product advocates. This growth capital will facilitate expanded market access, reimbursement support from payers, operational scaling in key markets, data acquisition, and funding operations while implementing new monetization strategies.


The infusion of Series B equity/crowdfunded growth capital will drive clinical adoption necessary for SmartUltrasound™ to establish itself as the diagnostic standard worldwide, laying the groundwork for robust revenue growth and profitability in 2026 and beyond.

CONFIDENTIAL



Koios Community Testimonials

CONFIDENTIAL



“
 Koios artificial intelligence nearly cuts my reading times in half, especially on more challenging and time consuming cases... those minutes really add up.

Amy Patel, MD
 Chief of Breast Imaging, Liberty Hospital & UNMC Medical School




“
 What Koios was able to do in 5 seconds typically requires 3 minutes, per nodule AND did so with perfect accuracy...

Dr. Julian Goh Park Nam
 Tan Tock Seng Hospital, Singapore



“
 Koios is transforming thyroid nodule characterization and markedly improving the lives of patients with nodules.
 Decreasing unnecessary biopsy for benign nodules while accurately identifying thyroid cancer, Koios powered by AI allows us to navigate a new world in next generation thyroid imaging.
 Your patients and referrers will thank you for being Koios confident!

Louis Mazzairelli, MD
 Radiologist, Yale New Haven Health/Lawrence + Memorial (USA)



“
 Koios AI has profoundly influenced our medical practices, bringing about a substantial reduction of nearly 50% in excessive follow-ups for BI-RADS 3 cases.
 Additionally, we've observed an almost one-fifth decrease in biopsy indications for BI-RADS 4 cases.
 Koios AI has effectively streamlined our processes, leading to improved efficiency in breast imaging.

Professor Erkin Aribal, MD
 Chief of Breast Imaging, Acozadem University (Turkey)

CONFIDENTIAL



“
 Artificial intelligence has the ability to make us... even better physicians than we might otherwise be.

Laurie Margolies, MD
 Chief of Breast Imaging, Mount Sinai Health System

CONFIDENTIAL

CBS Evening News Segment:

<https://www.cbsnews.com/newyork/news/doctors-tout-use-of-artificial-intelligence-to-detect-breast-cancer/>

Koios Medical, Inc

Koios Medical, Inc (NYC) has emerged as the global leader in AI software for accurately diagnosing cancer while improving clinical workflows by



Investment Opportunity Summary

for accurately diagnosing cancer while improving clinical workflows by applying proven machine learning to the lowest cost, safest and most widely available imaging modality in the world: ultrasound, sonography

Koios SmartUltrasound software is built upon proprietary machine learning and deep learning models and methods, utilizing a massive and expanding image dataset clinically proven to enhance diagnostic accuracy for breast and thyroid cancer while optimizing operational workflows.

The Company holds regulatory clearances both domestically and internationally (FDA, CE Marks) as software as a medical device (SaMD), providing clinical decision support to improve physician efficacy, efficiency, and productivity. This technology is currently utilized by a growing network of leading caregivers spanning over 20 countries.

Koios Medical is positioned for exponential growth over the next five years as the adoption of AI in radiology, particularly, gains traction in response to workforce constraints. This growth is supported by our accumulating body of positive clinical evidence, ongoing product innovations, a global distribution network, increasing user acceptance, and the rise in payer-supported reimbursement.

The Company is currently raising a Series B round of \$13M with \$8 million already committed and funded by a major international financial institutional investor (Mitsui & Co). An additional \$5 million is available for raising from the "Koios Community" through WeFunder.com/Koios.

Thank you.

Chad McClennan
President & CEO



Graham Anderson
CFO, CAO



CONFIDENTIAL